Evidence map›Paper›PMID 39206813›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

SARS-CoV-2 Evolution: Immune Dynamics, Omicron Specificity, and Predictive Modeling in Vaccinated Populations.

Xiaohan Zhang, Mansheng Li, Nana Zhang, Yunhui Li, Fei Teng, Yongzhe Li, Xiaomei Zhang, Xingming Xu, Haolong Li, Yunping Zhu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiaohan ZhangState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Mansheng LiState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Nana ZhangDepartment of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
Yunhui LiDepartment of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Fei TengEmergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing, 100020, China.
Yongzhe LiDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, China.
Xiaomei ZhangState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Xingming XuState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Haolong LiDepartment of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, China.
Yunping ZhuState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.
Yumin WangThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China.
Yan JiaProteomicsEra Medical Co. Ltd., Beijing, 102206, China.
Chengfeng QinDepartment of Virology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, 100071, China.
Bingwei WangSchool of Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Shubin GuoEmergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing, 100020, China.
Yajie WangDepartment of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, China.
Xiaobo YuState Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.ORCID 0000-0003-2352-9866

Funding

Beijing Municipal International Cooperation and Exchange Project Z231100002723004Beijing Municipal Natural Science Foundation L234034Beijing Municipal Natural Science Foundation M23010Capital Health Development Research Project 2024-1-1201Capital Health Development Research Project 2024-1-4093Guangdong-PHOENIX Center Joint Lab on Chinese Medicine YN2021DB03Guangdong-PHOENIX Center Joint Lab on Chinese Medicine YN2021DB06Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine ZYYCXTD-C-202204National Key R&D Program of China 2021YFA1301604National Key R&D Program of China 2022YFE0210400National Key R&D Program of China 2023YFC0872400Science and Technology Planning Project of Guangdong Province 2020B1111100006State Key Laboratory of Proteomics SKLP-O202007State Key Laboratory of Proteomics SKLP-O202205
6 · The paper itself

Abstract

Host immunity is central to the virus's spread dynamics, which is significantly influenced by vaccination and prior infection experiences. In this work, we analyzed the co-evolution of SARS-CoV-2 mutation, angiotensin-converting enzyme 2 (ACE2) receptor binding, and neutralizing antibody (NAb) responses across various variants in 822 human and mice vaccinated with different non-Omicron and Omicron vaccines is analyzed. The link between vaccine efficacy and vaccine type, dosing, and post-vaccination duration is revealed. The classification of immune protection against non-Omicron and Omicron variants is co-evolved with genetic mutations and vaccination. Additionally, a model, the Prevalence Score (P-Score) is introduced, which surpasses previous algorithm-based models in predicting the potential prevalence of new variants in vaccinated populations. The hybrid vaccination combining the wild-type (WT) inactivated vaccine with the Omicron BA.4/5 mRNA vaccine may provide broad protection against both non-Omicron variants and Omicron variants, albeit with EG.5.1 still posing a risk. In conclusion, these findings enhance understanding of population immunity variations and provide valuable insights for future vaccine development and public health strategies.

Indexed as

Antibodies, NeutralizingCOVID-19COVID-19 VaccinesSARS-CoV-2Angiotensin-Converting Enzyme 2AnimalsAntibodies, ViralHumansMiceMutationVaccinationVaccine EfficacyACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralCOVID-19 Vaccinesevolutionneutralizing antibodyprevalenceproteomicsSARS‐CoV‐2

Identifiers

PMID39206813
PMCPMC11516136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.